[Podcast] Closing the Distance in Cancer Care

Why It Matters

Localizing cancer care improves access, accelerates trial enrollment, and cuts patient travel costs, strengthening the overall oncology ecosystem.

Key Takeaways

• Community oncology now treats 40% of US cancer patients locally
• McKesson invests $500M in regional infusion network expansion
• Telehealth reduces travel time for chemotherapy by 30%
• Clinical trial enrollment rises 15% via community sites
• Patient satisfaction scores improve with local care access

Pulse Analysis

Community oncology has moved from a peripheral service to a central pillar of U.S. cancer care. Advances in infusion technology, electronic health records, and payer contracts have enabled independent clinics to deliver complex regimens once reserved for academic hospitals. As a result, roughly 40% of patients now receive chemotherapy, immunotherapy, or targeted agents at community sites, a share that has grown steadily over the past five years. This shift not only eases geographic barriers but also creates a more competitive market, prompting larger health systems to partner with or acquire local practices.

McKesson’s sponsorship of the podcast reflects its broader strategy to fuel that growth. The company recently pledged $500 million to expand a regional infusion network, integrating pharmacy logistics, data analytics, and tele‑oncology platforms. By standardizing drug preparation and delivery, McKesson helps community clinics meet the stringent safety and compliance standards required for high‑cost biologics. The infusion network also supports real‑time trial matching, allowing patients to enroll in cutting‑edge studies without traveling to distant research hubs, which has already lifted trial enrollment rates by about 15% in participating sites.

For patients, the convergence of local expertise, telehealth, and streamlined logistics translates into tangible benefits: reduced travel time—often by 30% for chemotherapy visits—lower out‑of‑pocket expenses, and higher satisfaction scores. Providers gain access to a broader therapeutic arsenal and data‑driven decision support, improving outcomes while preserving practice autonomy. As the industry continues to prioritize value‑based care, community oncology’s expansion is poised to become a key driver of both clinical innovation and cost containment in the fight against cancer.